---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264984450.md"
description: "Amgen: The results of the Phase 3 clinical trial of Vesalius-CV indicate that Repatha (evolocumab, a PCSK9 inhibitor) reduces the risk of first major cardiovascular events"
datetime: "2025-11-08T15:21:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264984450.md)
  - [en](https://longbridge.com/en/news/264984450.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264984450.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264984450.md) | [繁體中文](https://longbridge.com/zh-HK/news/264984450.md)


# 

Amgen: Results from the Phase III clinical trial of Vesalius-CV indicate that Repatha (evolocumab, a PCSK9 inhibitor) reduces the risk of first occurrence of major cardiovascular events

### Related Stocks

- [Amgen Inc. (AMGN.US)](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS | AMGN Stock News](https://longbridge.com/en/news/280887650.md)
- [Amgen Says Repatha Reduced Major Cardiovascular Event Risk by 31% in Diabetes Patients](https://longbridge.com/en/news/280995862.md)
- [Sitios Latinoamerica SAB de CV (LASITE) was upgraded to a Buy Rating at Scotiabank](https://longbridge.com/en/news/281147365.md)
- [CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results | CVSI Stock News](https://longbridge.com/en/news/280681002.md)
- [Merck's Enlicitide Decanoate Shows Greater LDL-C Reduction Than Oral Non-Statins At 8 Weeks](https://longbridge.com/en/news/281051985.md)